STARZ announced it will report its financial results for the third quarter of 2026, ending September 30, on October 29. The company will hold an analyst and investor call at 2:00 PM PT/5:00 PM ET after the market closes to discuss the results. STARZ is known for its premium entertainment content targeting women and underrepresented audiences, available across various digital platforms. Investors can listen to the live webcast or access a replay later that evening.
STARZ's upcoming third quarter earnings report and investor call provide context for media sector activity on Pluang. For readers following media stocks, here is Pluang's market snapshot as of Oct 02, 2026 03:42 WIB: Out of 45 priced US media stocks, 14 rose and 31 fell. Notable movers include Zillow Group Inc Class C (Z) at USD 27.75 with a 1-day change of +2.29% and a typical hold time of 37 days, Nerdwallet Inc (NRDS) at USD 8.58 with a 1-day change of -2.28% and 100% buy order activity, and Netflix Inc (NFLX) at USD 68.00 with a 1-day change of -2.27% and 92% buy order activity.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
